Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
Alnylam Pharmaceuticals drug Onpattro, an FDA-approved treatment for nerve pain caused by hereditary transthyretin amyloidosis, now has Phase 3 data showing it can also help […]